Jim Cramer Critiques Bristol-Myers Squibb: Missed Opportunities

Reported 3 days ago

In his recent discussion on CNBC, Jim Cramer provided insights into the pharmaceutical giant Bristol-Myers Squibb Co (NYSE:BMY), emphasizing the company's strategic missteps, particularly regarding ill-advised business spinoffs. While he praised its potential in handling schizophrenia with its COBENFY drug, he pointed out that the company’s low PE ratio reflects deeper issues in its pipeline. Additionally, Cramer highlighted the broader challenges facing tech stocks amidst market uncertainties, noting the significant impact of tariffs and taxes on their valuations.

Source: YAHOO

View details

You may also interested in these wikis

Back to all Wikis